Iron-Refractory Iron Deficiency Anemia: Pathophysiological Mechanisms, Hepcidin Dysregulation, and Emerging Diagnostic and Therapeutic Strategies

Iron-refractory iron deficiency anemia (IRIDA) is an uncommon hereditary hematological disorder characterized by persistent microcytic and hypochromic anemia, markedly reduced transferrin saturation, and inadequate hematological response to conventional oral iron supplementation. Its molecular pathogenesis is primarily associated with pathogenic variants in the TMPRSS6 gene, which impair matriptase-2 activity and disrupt physiological suppression of hepcidin, resulting in restricted intestinal iron absorption and reduced systemic iron availability. This narrative review examines the molecular mechanisms, hematological manifestations, diagnostic approaches, and therapeutic strategies associated with hereditary IRIDA, integrating published experimental and clinical evidence within an international framework that considers healthcare accessibility in Latin America. The reviewed findings demonstrate substantial biochemical differences between hereditary IRIDA and acquired iron deficiency anemia, particularly in the transferrin saturation-to-hepcidin ratio, while highlighting the potential diagnostic value of hepcidin-based indices. Hematological investigations reveal considerable phenotypic heterogeneity, including variations in hemoglobin concentration, erythrocyte indices, and iron parameters among individuals with TMPRSS6-associated abnormalities. Therapeutic evidence indicates that intravenous iron may produce partial hematological improvement despite persistent abnormalities in iron regulation, whereas selected patients with IRIDA-related phenotypes may demonstrate variable responses to oral supplementation. Emerging interventions targeting hepcidin synthesis and the hepcidin–ferroportin axis offer promising mechanistic approaches, although their clinical effectiveness requires further validation. The available evidence remains limited by small patient populations, heterogeneous diagnostic criteria, and insufficient comparative therapeutic investigations. Overall, the findings emphasize distinguishing hereditary IRIDA from acquired refractory iron deficiency through integrated clinical, biochemical, and molecular assessment.

Authors

Publication Details

Journal
IECCMEXICO
Published
2026-11-15
DOI
https://doi.org/10.64784/405
Primary Topic
Iron Metabolism and Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Iron-Refractory Iron Deficiency Anemia: Pathophysiological Mechanisms, Hepcidin Dysregulation, and Emerging Diagnostic and Therapeutic Strategies

Luis Miguel Mora López
IECCMEXICO
Iron Metabolism and Disorders
article

Iron-Refractory Iron Deficiency Anemia: Pathophysiological Mechanisms, Hepcidin Dysregulation, and Emerging Diagnostic and Therapeutic Strategies

Luis Miguel Mora López
article en

Abstract

Iron-refractory iron deficiency anemia (IRIDA) is an uncommon hereditary hematological disorder characterized by persistent microcytic and hypochromic anemia, markedly reduced transferrin saturation, and inadequate hematological response to conventional oral iron supplementation. Its molecular pathogenesis is primarily associated with pathogenic variants in the TMPRSS6 gene, which impair matriptase-2 activity and disrupt physiological suppression of hepcidin, resulting in restricted intestinal iron absorption and reduced systemic iron availability. This narrative review examines the molecular mechanisms, hematological manifestations, diagnostic approaches, and therapeutic strategies associated with hereditary IRIDA, integrating published experimental and clinical evidence within an international framework that considers healthcare accessibility in Latin America. The reviewed findings demonstrate substantial biochemical differences between hereditary IRIDA and acquired iron deficiency anemia, particularly in the transferrin saturation-to-hepcidin ratio, while highlighting the potential diagnostic value of hepcidin-based indices. Hematological investigations reveal considerable phenotypic heterogeneity, including variations in hemoglobin concentration, erythrocyte indices, and iron parameters among individuals with TMPRSS6-associated abnormalities. Therapeutic evidence indicates that intravenous iron may produce partial hematological improvement despite persistent abnormalities in iron regulation, whereas selected patients with IRIDA-related phenotypes may demonstrate variable responses to oral supplementation. Emerging interventions targeting hepcidin synthesis and the hepcidin–ferroportin axis offer promising mechanistic approaches, although their clinical effectiveness requires further validation. The available evidence remains limited by small patient populations, heterogeneous diagnostic criteria, and insufficient comparative therapeutic investigations. Overall, the findings emphasize distinguishing hereditary IRIDA from acquired refractory iron deficiency through integrated clinical, biochemical, and molecular assessment.

IECCMEXICOVol. 5(2)
Iron Metabolism and Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon